STATEMENT UNDE	R 37 CFR 3.73(b)		
Applicant/Patent Owner: Viventia Biotech Inc.			
Application No./Patent No.: 7,115,722	,722 Filed/Issue Date: October 03, 2006		
Titled: ANTIGEN BINDING FRAGMENTS THAT SPECIFICAL ENCODING THE FRAGMENTS, AND USE THEREO CANCERS	· ·		
Viventia Biotech Inc. a corpora	ation		
(Name of Assignee) (Type of	f Assignee, e.g., corporation, partnership, university, government agency, etc.		
states that it is:			
1. X the assignee of the entire right, title, and interest in;			
2. an assignee of less than the entire right, title, and interest (The extent (by percentage) of its ownership interest is	in %); or		
3. the assignee of an undivided interest in the entirety of (a c	complete assignment from one of the joint inventors was made)		
the patent application/patent identified above, by virtue of either:			
A. An assignment from the inventor(s) of the patent application the United States Patent and Trademark Office at Reel copy therefore is attached.	on/patent identified above. The assignment was recorded in, Frame, or for which a		
OR			
B. X A chain of title from the inventor(s), of the patent application	on/patent identified above, to the current assignee as follows:		
1, From: DAN, Michael D.	To: Novopharm Biotech Inc.		
The document was recorded in the United State Reel 009884 , Frame 0941	es Patent and Trademark Office at, or for which a copy thereof is attached.		
2. From: KAPLAN, Howard A.	To: Novopharm Biotech Inc.		
The document was recorded in the United State	es Patent and Trademark Office at		
Reel 009884 , Frame 0941	or for which a copy thereof is attached.		
3. From: MAITI, Pradip K.	To: Novopharm Biotech Inc.		
The document was recorded in the United State	es Patent and Trademark Office at		
Reel 009884 , Frame 0941	, or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a s	supplemental sheet(s).		
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence or concurrently is being, submitted for recordation pursuant to	ce of the chain of title from the original owner to the assignee was, 37 CFR 3.11.		
[NOTE: A separate copy (i.e., a true copy of the original assignment in the	nment document(s)) must be submitted to Assignment Division in e records of the USPTO. <u>See MPEP</u> 302.08]		
The undersigned (whose title is supplied below) is authorized to act o	n behalf of the assignee.		
/N. Nicole Endejann/	March 2, 2013		
Signature	Date		
N. Nicole Endejann, USPTO Reg. No. 50229	Patent Attorney		
Printed or Typed Name	Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Supp	olemental	Sheet to	Statement	Under 3	37 (C.F.R.	Ş	3.73(b)
------	-----------	----------	-----------	---------	------	--------	---	---------

Continuation of B:

4. From: Novopharm Biotech Inc.	o: Viventia Biotech Inc.
The document was recorded in the United States Patent a	nd Trademark Office at
Reel <u>014398</u> Frame <u>0718</u>	, or for which a copy thereof is attached.
5. From: Novopharm Biotech Inc.	o: Viventia Biotech Inc.
The document was recorded in the United States Patent a	nd Trademark Office at
The document was recorded in the emice states ratem a	na Trademain Ginee at

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 A record in this system of records may be disclosed, as a routine use, to another federal
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.